EULAR 2025, video met Elise van Mulligen, LUMC
June 2025
RA
ACPA
Elise van Mulligen
EULAR 2025
POS0582
TREAT EARLIER Trial:
POS0582 – Risk-Stratified Cost-Utility Analysis of the TREAT EARLIER Trial: One-Year Methotrexate Treatment for Clinically Suspect Arthralgia is Cost-Effective in ACPA negative but not in ACPA positive patients with an increased risk for RA
Wilt u meer lezen? Log dan in.
Gerelateerde items
